Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Short-term Investments (2016 - 2025)

Gsk has reported Short-term Investments over the past 9 years, most recently at $161.0 million for Q4 2025.

  • Quarterly results put Short-term Investments at $161.0 million for Q4 2025, up 15.05% from a year ago — trailing twelve months through Dec 2025 was $161.0 million (up 15.05% YoY), and the annual figure for FY2025 was $161.0 million, up 15.05%.
  • Short-term Investments for Q4 2025 was $161.0 million at Gsk, up from $139.9 million in the prior quarter.
  • Over the last five years, Short-term Investments for GLAXF hit a ceiling of $4.8 billion in Q4 2022 and a floor of $139.9 million in Q4 2024.
  • Median Short-term Investments over the past 4 years was $1.4 billion (2023), compared with a mean of $2.0 billion.
  • Biggest five-year swings in Short-term Investments: plummeted 94.89% in 2024 and later increased 15.05% in 2025.
  • Gsk's Short-term Investments stood at $4.8 billion in 2022, then plummeted by 42.94% to $2.7 billion in 2023, then plummeted by 94.89% to $139.9 million in 2024, then rose by 15.05% to $161.0 million in 2025.
  • The last three reported values for Short-term Investments were $161.0 million (Q4 2025), $139.9 million (Q4 2024), and $2.7 billion (Q4 2023) per Business Quant data.